EHA 2016 | SGN-CD33A with hypomethylating therapy produces high remission rates among older AML patients

Name: SGN-CD33A with hypomethylating therapy produces high remission rates among older AML patients
Uploaded: 2016-06-09T00:00:00.000Z
Duration: 5 min 7 s
Description: Press brief by Amir Fathi, MD of the Massachusetts General Hospital, Boston, MA, on SGN-CD33A combined with hypomethylating therapy, which produces high remission rates among older patients with AML at the 2016 Annual Meeting of the European Association of Hematology (EHA), held in Copenhagen, Denmark.

Amir Fathi • 9 Jun 2016

EHA 2016

Acute Myeloid Leukemia

Press brief by Amir Fathi, MD of the Massachusetts General Hospital, Boston, MA, on SGN-CD33A combined with hypomethylating therapy, which produces high remission rates among older patients with AML at the 2016 Annual Meeting of the European Association of Hematology (EHA), held in Copenhagen, Denmark.